StockData
Valneva SE logo

Valneva SE (VALN) stock

VALNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 17, 2026Score 1/30
$5.34−0.23 (-4.04%)

Close on Nov 18, 2026Market cap $463.35MP/E –Yield –

Valneva revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Valneva's revenue for the twelve months ending Jun 30, 2026 was €142.94M, down 27.2% year over year. For fiscal 2025 it was €174.66M, up 3.0% from the year before. The highest annual figure on record is €361.30M in fiscal 2022.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025€174.66M+3.0%
FY2024Dec 31, 2024€169.58M+10.3%
FY2023Dec 31, 2023€153.71M-57.5%
FY2022Dec 31, 2022€361.30M+3.8%
FY2021Dec 31, 2021€348.09M+215.5%
FY2020Dec 31, 2020€110.32M-12.6%
FY2019Dec 31, 2019€126.20M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026€34.94M-27.7%
Q1 FY2026Mar 31, 2026€30.90M-37.2%
Q4 FY2025Dec 31, 2025€47.69M-9.9%
Q3 FY2025Sep 30, 2025€29.41M-35.8%
Q2 FY2025Jun 30, 2025€48.33M+27.0%
Q1 FY2025Mar 31, 2025€49.23M+50.3%
Q4 FY2024Dec 31, 2024€52.94M+26.4%
Q3 FY2024Sep 30, 2024€45.82M+20.4%
Q2 FY2024Jun 30, 2024€38.06M-5.4%
Q1 FY2024Mar 31, 2024€32.75M-2.3%
Q4 FY2023Dec 31, 2023€41.90M-62.4%
Q3 FY2023Sep 30, 2023€38.07M-75.7%
Q2 FY2023Jun 30, 2023€40.24M-43.6%
Q1 FY2023Mar 31, 2023€33.51M+53.4%
Q4 FY2022Dec 31, 2022€111.40M-60.0%
Q3 FY2022Sep 30, 2022€156.68M+601.2%
Q2 FY2022Jun 30, 2022€71.38M+193.9%
Q1 FY2022Mar 31, 2022€21.85M-5.9%
Q4 FY2021Dec 31, 2021€278.24M–
Q3 FY2021Sep 30, 2021€22.35M–
Q2 FY2021Jun 30, 2021€24.29M–
Q1 FY2021Mar 31, 2021€23.22M–

More Valneva figures

See a number that looks wrong?